• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT IRELAND DIAGNOSTICS DIVISION IMMUNOGLOBULIN M; IGM, ANTIGEN, ANTISERUM, CONTROL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT IRELAND DIAGNOSTICS DIVISION IMMUNOGLOBULIN M; IGM, ANTIGEN, ANTISERUM, CONTROL Back to Search Results
Catalog Number 09P63-24
Device Problem Installation-Related Problem (2965)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 03/28/2024
Event Type  malfunction  
Manufacturer Narrative
Completed information for section a1 - patient identifier = (b)(6).An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.
 
Event Description
The customer reported a falsely decreased immunoglobulin m on the alinity c processing module for one patient.The following results were provided: sid (b)(6) - initial run (standard 1:5 dilution) = >16.9 g/l, automatic rerun of undiluted sample = 1.045 g/l; rerun with 1:20 manual dilution = 40.724 g/l.Configuration of the assay in the alinity c software was performed in august 2023.If the analyzer is configured as g/l the range would be 0-0.25 and if configured as mg/dl the range would be 0-25.The units of measure were entered as g/l, but the range was not updated to 0-0.25 g/l.The analyzer configuration of the rerun rule was to perform an automatic rerun of an undiluted sample if the value fell within the range configured in the software.Since the alinity software was configured with a range of 0-25 g/l, the automatic rerun protocol was incorrect, and the sample was repeated as an undiluted sample.The sample needed to be diluted prior to rerunning.There was no impact to patient management reported.
 
Event Description
The customer reported a falsely decreased immunoglobulin m on the alinity c processing module for one patient.The following results were provided: sid (b)(6) initial run (standard 1:5 dilution) = >16.9 g/l, automatic rerun of undiluted sample = 1.045 g/l; rerun with 1:20 manual dilution = 40.724 g/l configuration of the assay in the alinity c software was performed in august 2023.If the analyzer is configured as g/l the range would be 0-0.25 and if configured as mg/dl the range would be 0-25.The units of measure were entered as g/l, but the range was not updated to 0-0.25 g/l.The analyzer configuration of the rerun rule was to perform an automatic rerun of an undiluted sample if the value fell within the range configured in the software.Since the alinity software was configured with a range of 0-25 g/l, the automatic rerun protocol was incorrect, and the sample was repeated as an undiluted sample.The sample needed to be diluted prior to rerunning.There was no impact to patient management reported.
 
Manufacturer Narrative
The complaint investigation included a review of data and information provided by the customer, search for similar complaints, ticket trending review, device history record review and labeling review.Return testing was not completed as returns were not available.Data and information provided by the customer confirm the complaint issue without indication for any additional issues identified.A search for similar complaints did not identify an increase in complaint activity for lot 60053ud00.Ticket trending review did not identify any trends for the issue for the product.A device history record review did not identify any nonconformances or deviations associated with lot 60053ud00 and complaint issue.Labeling was reviewed and sufficiently addresses the customer¿s issue.Based on the investigation, no systemic issue or deficiency of the immunoglobulin m (igm) reagent for lot 60053ud00 was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMMUNOGLOBULIN M
Type of Device
IGM, ANTIGEN, ANTISERUM, CONTROL
Manufacturer (Section D)
ABBOTT IRELAND DIAGNOSTICS DIVISION
lisnamuck
co. longford
longford N39E9 32
EI  N39E932
Manufacturer (Section G)
ABBOTT IRELAND DIAGNOSTICS DIVISION
lisnamuck
co. longford
longford N39E9 32
EI   N39E932
Manufacturer Contact
nicole jenne
max-planck-ring 2
post market surveillance
wiesbaden 65205
GM   65205
6122582960
MDR Report Key19070813
MDR Text Key340679718
Report Number3005094123-2024-00177
Device Sequence Number1
Product Code DFT
UDI-Device Identifier00380740169916
UDI-Public(01)00380740169916(17)241130(10)60053UD00
Combination Product (y/n)N
Reporter Country CodeBE
PMA/PMN Number
K983132
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 05/24/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number09P63-24
Device Lot Number60053UD00
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 03/28/2024
Initial Date FDA Received04/09/2024
Supplement Dates Manufacturer Received05/17/2024
Supplement Dates FDA Received05/24/2024
Was Device Evaluated by Manufacturer? Yes
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ALNTY C PROCESSING MODU, 03R67-01, AC01476; ALNTY C PROCESSING MODU, 03R67-01, AC01476
-
-